Market Cap
$162.6B
PFE
PFIZER INC
$27.59 ▼ -1.88%
Prev close $28.12Market cap$162.6B
ConsensusSell
12-mo target$28.91 (+5.1%)
▲ Neutral
Analyst conviction 4/10
Insider Buying Cluster (4 insiders)High Impact Filing (7/10)28 New Institutional Positions22 Institutional ExitsCongressional Activity (1) Biotech & Drug Discovery
Snapshot
The big-picture read on PFE right now — valuation, ownership and activity at a glance.
Cap Size
Large Cap
Analyst Consensus
Hold (39%)
Inst. Holders
50 funds
Inst. Value
$69.3B
Inst. Activity
28 buys / 22 sells
Insider Activity
$3.0M buy / $134.7K sell
Insider Net $
$2.8M
Social Sentiment
66° Warm
SEC Reports
16
Congressional
7 trades
Price chart 30d -4.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 clinical_trial_readout
T-90d Trial Readout: PF-07104091 monotherapy dose escalation (Phase 2)
Trial: PF-07104091 as a Single Agent and in Combination Therapy Sponsor: Pfizer Phase: Phase 2 | Sta
Sep 30, 2026 Insider
BOURLA ALBERT was granted 21 shares
Chairman & CEO @ $28.52 ($598.92)
Sep 25, 2026 Insider
SMITH JAMES C was granted 1,569.585 shares
Director @ $28.67 ($45.0K)
Sep 25, 2026 Insider
Taraporevala Cyrus was granted 1,307.987 shares
Director @ $28.67 ($37.5K)
Sep 23, 2026 Event
Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC 0409-5820-11, Carton NDC 0409-5820-01.
Class II: Lack of Assurance of Sterility
Aug 13, 2026 Event
BELL v. PFIZER, INC.
Court ruling (paed) — Docket: 2:26-cv-02979
Jul 7, 2026 Congress
Jul 6, 2026 SEC Ro Khanna buy
$1,001 - $15,000 — House
HSBC downgrades PFE to Hold — PT $28 (-12.5%)
ANALYST-DOWNGRADE — Impact 4/10
Analyst ratings buy % -13.3%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
39% rate it Buy or better · 36 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 10, 2026 | HSBC | MAINTAIN | Hold | 55% |
| Aug 7, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Jul 13, 2026 | BMO Capital | MAINTAIN | Outperform | 53% |
| Jul 13, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Jul 10, 2026 | B of A Securities | MAINTAIN | Neutral | 54% |
| Jul 8, 2026 | JP Morgan | MAINTAIN | Neutral | 55% |
| Jul 6, 2026 | Cantor Fitzgerald | REITERATE | Neutral | 49% |
| Jul 6, 2026 | HSBC | DOWNGRADE | Hold | 55% |
| Jun 10, 2026 | RBC Capital | UPGRADE | Sector Perform | 55% |
| Apr 29, 2026 | Citigroup | MAINTAIN | Neutral | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 8 | 20 | 1 | 1 | 39% | |
| Aug 1, 2026 | 6 | 8 | 20 | 1 | 1 | 39% | |
| Jul 1, 2026 | 6 | 9 | 19 | 1 | 1 | 42% | |
| Jun 1, 2026 | 6 | 9 | 18 | 2 | 1 | 42% | |
| May 1, 2026 | 5 | 11 | 17 | 2 | 1 | 44% | |
| Apr 1, 2026 | 6 | 9 | 17 | 2 | 1 | 43% | |
| Mar 1, 2026 | 5 | 9 | 18 | 2 | 1 | 40% | |
| Feb 1, 2026 | 5 | 10 | 17 | 0 | 1 | 45% |
Price targets
Where 26 covering analysts think PFE trades over the next 12 months.
$28.91 +5.1% upside Buy
Current$27.52 Low$25.00 Median$28.00 High$35.75 26 analysts
$25.00$35.75
Analyst rating Buy· 2.5/5 as of Oct 2, 2026
Social media sentiment mood -16.7%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
66°
Warm
BearishNeutralBullish
Recent posts
PFE: Pfizer
▲ 1 · 💬 0· ⚡ 0.5
US Large Cap Highest Dividend Payers, Excluding REITs, Mortgage REITs, BDCs, Preferred Stocks, Funds & Partnership UnitsStock Analysis
▲ 1 · 💬 0· ⚡ 0.5
US Large Cap Highest Dividend Payers, Excluding REITs, Mortgage REITs, BDCs, Preferred Stocks, Funds & Partnership Units
▲ 1 · 💬 2· ⚡ 0.5
Red day from FED..do you close profitable covered calls, roll or sit on hands?
▲ 1 · 💬 0· ⚡ 0.5
12 names where short-dated call buying is forcing dealers to hedge. All expire Friday.
▲ 1 · 💬 7· ⚡ 0.5
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
16 SEC filing reports analyzed · 5 bullish, 2 bearish, 0 mixed, 9 neutral · avg impact 3.3/10.
BEARISHANALYST-DOWNGRADE4/10
HSBC downgrades PFE to Hold — PT $28 (-12.5%)
Jul 6, 2026
BULLISHANALYST-UPGRADE3/10
CICC initiates PFE at Outperform with $33 PT — +15.6% upside vs. consensus mean
Apr 16, 2026
NEUTRALANALYST-UPGRADE2/10
RBC Capital upgrades PFE to Sector Perform — PT $25 (-2.7%)
Jun 10, 2026
BULLISHINSIDER-BUY5/10
Pfizer Chairman & CEO Albert Bourla made an open-market purchase of $1.0M worth of shares at $26.34
Aug 17, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
Clinical Trial
Linezolid Dosing Strategies in Drug-Resistant TB
Phase Phase 2 — COMPLETED
Oct 2, 2026
Clinical Trial
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
Phase Phase 2 — COMPLETED
Oct 2, 2026
Clinical Trial
A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy
Phase Phase 2 — COMPLETED
Oct 2, 2026
Clinical Trial
PF-07104091 as a Single Agent and in Combination Therapy
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Oct 2, 2026
Clinical Trial
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Phase Phase 3 — ACTIVE_NOT_RECRUITING
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.76 | $0.59–$0.94 | -12.8% | -0.0% | 1↑ 14↓ | $15.9B | 18 |
| Next Q | $0.71 | $0.60–$0.81 | 7.3% | -0.0% | 11↑ 4↓ | $16.9B | 18 |
| Current FY | $2.97 | $2.88–$3.10 | -7.6% | -0.0% | 15↑ 4↓ | $62.2B | 25 |
| Next FY | $2.90 | $2.52–$3.16 | -2.6% | +0.0% | 15↑ 4↓ | $59.9B | 25 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.759 | — |
| 7d ago | $0.759 | -0.000 |
| 30d ago | $0.759 | -0.000 |
| 60d ago | $0.811 | -0.052 |
| 90d ago | $0.849 | -0.090 |
Institutional ownership
Which big funds own PFE (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $69.3B total value (2,858,671,425 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 28 institutions added/increased vs 22 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 529,670,433 | $12.8B | 18.4% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 372,149,852 | $9.0B | 12.9% | — |
| STATE STREET CORP | 307,090,897 | $7.4B | 10.7% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 135,275,782 | $3.2B | 4.7% | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 119,235,030 | $2.9B | 4.1% | — |
| Fisher Asset Management, LLC | 109,067,291 | $2.6B | 3.8% | — |
| MORGAN STANLEY | 96,345,452 | $2.3B | 3.3% | — |
| NORGES BANK | 61,505,586 | $1.5B | 2.1% | NEW |
| NORTHERN TRUST CORP | 59,084,573 | $1.4B | 2.1% | — |
| Bank of New York Mellon Corp | 57,879,546 | $1.4B | 2.0% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| NORGES BANK | NEW | — | 61,505,586 | — | $1.5B |
| WELLINGTON MANAGEMENT GROUP LLP | TRIM | 49,916,961 | 27,826,078 | -44.3% | $670.1M |
| CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | ADD | 10,840,185 | 17,261,993 | +59.2% | $415.7M |
| AMERIPRISE FINANCIAL INC | TRIM | 19,519,056 | 14,364,565 | -26.4% | $345.9M |
| Assenagon Asset Management S.A. | ADD | 6,073,170 | 11,902,374 | +96.0% | $286.6M |
| VICTORY CAPITAL MANAGEMENT INC | TRIM | 15,508,999 | 9,152,541 | -41.0% | $220.4M |
| PRUDENTIAL FINANCIAL INC | ADD | 5,968,365 | 7,718,545 | +29.3% | $185.9M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | DOUBLED | 1,186,035 | 6,547,246 | +452.0% | $157.7M |
| D. E. Shaw & Co., Inc. | TRIM | 12,467,262 | 5,414,297 | -56.6% | $130.4M |
| Diamond Hill Capital Management, LLC (Investment Advisor) | TRIM | 6,108,570 | 4,210,499 | -31.1% | $101.4M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
13 insiders, 50 transactions. Net $2.8M — $3.0M bought, $134.7K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | BOURLA ALBERT | Chairman & CEO | AWARD | 21 | $28.52 | $598.92 |
| Sep 25, 2026 | SMITH JAMES C | Director | AWARD | 1,569.585 | $28.67 | $45.0K |
| Sep 25, 2026 | Taraporevala Cyrus | Director | AWARD | 1,307.987 | $28.67 | $37.5K |
| Sep 25, 2026 | NARAYEN SHANTANU | Director | AWARD | 1,743.983 | $28.67 | $50.0K |
| Sep 25, 2026 | Quincey James | Director | AWARD | 1,351.587 | $28.67 | $38.7K |
| Sep 25, 2026 | Buckley Mortimer J | Director | AWARD | 1,307.987 | $28.67 | $37.5K |
| Sep 25, 2026 | Echevarria Joseph | Director | AWARD | 1,613.185 | $28.67 | $46.3K |
| Sep 15, 2026 | BOURLA ALBERT | Chairman & CEO | AWARD | 22 | $27.55 | $606.10 |
| Aug 31, 2026 | BOURLA ALBERT | Chairman & CEO | AWARD | 21 | $28.46 | $597.66 |
| Aug 14, 2026 | BOURLA ALBERT | Chairman & CEO | AWARD | 22 | $26.79 | $589.38 |
Congressional trades
PFE trades disclosed by members of Congress, with disclosure delay.
6 members · 4 buys / 3 sells
| Date | Member | Party | Chamber | Type | Amount | Asset | Disclosed |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | Pfizer Inc | Aug 12, 2026(37d) |
| Jun 8, 2026 | Tommy Tuberville | R | SENATE | SELL | $15,001 - $50,000 | Pfizer Inc | Jul 16, 2026(38d) |
| Apr 13, 2026 | Ro Khanna | D | HOUSE | BUY | $1,001 - $15,000 | Pfizer Inc | May 13, 2026(31d) |
| Feb 10, 2026 | Gilbert Cisneros | D | HOUSE | BUY | $1,001 - $15,000 | Pfizer Inc | Mar 10, 2026(29d) |
| Feb 3, 2026 | Susan Collins | R | SENATE | BUY | $15,001 - $50,000 | Pfizer Inc | Mar 26, 2026(51d) |
| Mar 10, 2025 | Carol Miller | R | HOUSE | SELL | $15,001 - $50,000 | Pfizer Inc | Aug 14, 2026(523d) |
| Nov 26, 2024 | Michael Rulli | R | HOUSE | SELL | $1,001 - $15,000 | Pfizer Inc | Aug 10, 2026(623d) |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PFE.
Shares short
155,202,257
Settlement Sep 15, 2026
Change vs prior
+2.4%
Semi-monthly cycle
Days to cover
4.9
At avg daily volume
Of shares outstanding
≈2.7%
Estimate — not % of float
All PFE filing & press-release reports (16)
- HSBC downgrades PFE to Hold — PT $28 (-12.5%)Jul 6, 2026
- CICC initiates PFE at Outperform with $33 PT — +15.6% upside vs. consensus meanApr 16, 2026
- RBC Capital upgrades PFE to Sector Perform — PT $25 (-2.7%)Jun 10, 2026
- INSIDER-BUY reportAug 17, 2026
- COURT-RULING reportAug 15, 2026
- CLUSTER reportAug 12, 2026
- CLUSTER reportAug 7, 2026
- CLUSTER reportAug 6, 2026
- 8-K reportAug 4, 2026
- COURT-RULING reportAug 1, 2026
- COURT-RULING reportJul 27, 2026
- 8-K reportJun 18, 2026
- 8-K reportJun 18, 2026
- COURT-RULING reportJun 17, 2026
- 8-K reportMay 5, 2026
- DEFA14A reportMar 12, 2026